Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Print
ISSN
0334-018X
See all formats and pricing
More options …
Volume 29, Issue 5

Issues

Pituitary gigantism: a retrospective case series

Ana L. Creo
  • Corresponding author
  • Division of Pediatric and Adolescent Medicine, Mayo Clinic, 200 1st St SW, Rochester MN, 55905, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Aida N. Lteif
Published Online: 2016-02-17 | DOI: https://doi.org/10.1515/jpem-2015-0269

Abstract

Background: Pituitary gigantism (PG) is a rare pediatric disease with poorly defined long-term outcomes. Our aim is to describe the longitudinal clinical course in PG patients using a single-center, retrospective cohort study.

Methods: Patients younger than 19 years diagnosed with PG were identified. Thirteen cases were confirmed based on histopathology of a GH secreting adenoma or hyperplasia and a height >2 SD for age and gender. Laboratory studies, initial pathology, and imaging were abstracted.

Results: Average age at diagnosis was 13 years with an average initial tumor size of 7.4×3.8 mm. Initial transsphenoidal surgery was curative in 3/12 patients. Four of the nine patients who failed the initial surgery required a repeat procedure. Octreotide successfully normalized GH levels in 1/6 patients with disease refractory to surgery (1/6). Two out of five patients received pegvisomant after failing octreotide but only one patient responded to treatment. Five patients were ultimately treated with radiosurgery or radiation patients were followed for an average of 10 years.

Conclusions: PG is difficult to treat. In most patients, the initial transsphenoidal surgery failed to normalize GH levels. If the initial surgery was unsuccessful, repeat surgery was unlikely to control GH secretion. Treatment with octreotide or pegvisomant was successful in less than half the patients failing surgery. Radiosurgery was curative, but is not an optimal treatment for pediatric patients. Despite the small sample, our study suggests that the treatment outcome of pediatric PG may be different than adults.

Keywords: Adenoma; gigantism; growth hormone; pituitary

References

  • 1.

    Zampieri P, Scanarini M, Sicolo N, Andrioli G, Mingrino S. The acromegaly gigantism syndrome. Report of four cases treated surgically. Surg Neurol 1983;20:498–503.Google Scholar

  • 2.

    Lu P, Silink M, Johnston I, Cowell C, Jimenez M. Pituitary gigantism. Arch Dis Child 1992;67:1039–41.Google Scholar

  • 3.

    Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 2008;93:2953–6.Web of ScienceGoogle Scholar

  • 4.

    Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, et al. Low prevalence of Gs alpha mutations in somatotroph adenomas of children and adolescents. Cancer Genet Cytogenet 2006;166:146–51.Google Scholar

  • 5.

    Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, et al. Gigantism and Acromegaly due to Xq26 Microduplications and GPR101 Mutation. N Engl J Med 2014; 317:2363–74.Google Scholar

  • 6.

    Ciresi A, Amato M, Galluzo A, Giordano C. Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy. J Endocrinol Invest 2011;34:162–3.Web of ScienceGoogle Scholar

  • 7.

    Fraioli B, Ferrante L, Celli P. Pituitary adenomas with onset during puberty. Features and treatment. J Neurosurg 1983;59:590–5.Google Scholar

  • 8.

    Kane L, Leinung M, Scheithauer B, Bergstralh E, Laws E, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994;79:1135–40.Google Scholar

  • 9.

    Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 2008;35:1014–9.Google Scholar

  • 10.

    Leinung M, Kane L, Scheithauer B, Carpenter P, Laws E, Zimmerman D. Long term follow-up of transsphenoidal surgery for the treatment of Cushing’s disease in childhood. J Clin Endocrinol Metab 1995;80:2475–9.Google Scholar

  • 11.

    Gilbert J, Ketchen M, Kane P, Mason T, Baister E, et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003; 6:11–8.Google Scholar

  • 12.

    Dotsch J, Kiess W, Hänze J, Repp R, Lüdecke D, et al. Gs-alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996; 81:3839–42.Google Scholar

  • 13.

    Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, et al. Five-year followup of a 13-year-old boy with pituitary adenoma causing gigantism-effect of octreotide therapy. Horm Res 2004;61:182–9.Google Scholar

  • 14.

    Queirolo S, Gallarotti F, Capuano E, Garre M, Spaziante R, et al. Gigantism with pituitary macroadenoma: an unusual variant of McCune-Albright syndrome. J Clin Endocrinol Metab 2009;22:177–9.Google Scholar

  • 15.

    Rix M, Laurberg P, Hoejberg A, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 2005;153:195–201.Google Scholar

  • 16.

    Mussig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, et al. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes 2007;115:198–202.Google Scholar

  • 17.

    Scholl U, Goh G, Stölting G, de Oliveira RC, Choi M, et al. Somatic and germline aldosterone-producing adenomas and primary aldosteronism. Nature Genetics 2013;45:1050–4.Google Scholar

About the article

Corresponding author: Ana L. Creo, Division of Pediatric and Adolescent Medicine, Mayo Clinic, 200 1st St SW, Rochester MN, 55905, USA, Phone: 507-284-3379, E-mail:


Received: 2015-07-10

Accepted: 2015-12-14

Published Online: 2016-02-17

Published in Print: 2016-05-01


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 5, Pages 597–602, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2015-0269.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
William Rojas García, Henry Tovar Cortes, and Andrés Florez Romero
Archives of Endocrinology and Metabolism, 2019
[2]
Daisuke Watanabe, Hideaki Yagasaki, Satoru Kojika, Masakazu Ogiwara, Hiroyuki Kinouchi, Takaya Nakane, and Takeshi Inukai
Endocrine Journal, 2019, Volume 66, Number 5, Page 403
[3]
Lina Raffaella Barzaghi, Marco Losa, Jody Filippo Capitanio, Luigi Albano, Giovanna Weber, and Pietro Mortini
Neurosurgery, 2018
[4]
Zenan Xia, Xiaopeng Guo, Qing Zhou, Jie Wu, Wei Lian, Yong Yao, Kan Deng, Ming Feng, Renzhi Wang, and Bing Xing
World Neurosurgery, 2018
[5]
Liliya Rostomyan, Iulia Potorac, Pablo Beckers, Adrian F. Daly, and Albert Beckers
Annales d'Endocrinologie, 2017, Volume 78, Number 2, Page 123
[6]
Nicholas A. Tritos and Beverly M. K. Biller
Pituitary, 2017, Volume 20, Number 1, Page 129

Comments (0)

Please log in or register to comment.
Log in